All patients with advanced lung adenocarcinoma should undergo testing for EGFR and ALK mutations to determine their eligibility for targeted therapies, according to a jointly developed guideline from three organizations. Read more here.
Study mentioned: Lindeman NI, et al. Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol. 2013 Apr 2. [Epub ahead of print] PMID: 23552377
No comments:
Post a Comment